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Sinonasal neuroendocrine carcinomaGiant prolactinomas are deﬁned as pituitary tumors greater than 4 cm, often associated with very high prolactin
level (N1000 ng/mL). They are relatively rare tumors and can present differently from typical prolactinomas.
They can be highly invasive, resulting in acute neurological complication at the time of presentation.We present
a case of a youngwomanwith giant prolactinoma initiallymisdiagnosed as sinonasal neuroendocrine carcinoma.
The acute presentation of headache, ptosis and impending brain herniation, requiring emergent ventriculostomy
and intubation, led to the clinical suspicion of a more sinister diagnosis. Transnasal biopsy of the mass was
consistent with sinonasal neuroendocrine carcinoma, and chemotherapy was planned. Laboratory testing,
however, revealed an elevated prolactin (27,400 ng/mL, after 1:100 dilution). Re-review of pathology with
additional immunohistochemical staining was requested and conﬁrmed the diagnosis of prolactinoma. After
5 months of cabergoline treatment, prolactin level has decreased to 118 ng/mL. There has been a marked reduc-
tion in tumor size and an almost complete resolution of neurological symptoms. Given their atypical presentation
and potential for sharing common immunohistochemical stains with other neuroendocrine neoplasms, giant
prolactinomas extending into the nasal cavity can be misdiagnosed as other neuroendocrine neoplasms which
may develop at this site. Accurate diagnosis is imperative to prevent unnecessary surgery and/or radiation and
to ensure implementation of dopamine agonist therapy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Giant prolactinomas are generally deﬁned as pituitary tumors greater
than 4 cm in diameter with high baseline prolactin (PRL) levels (often
above 1000 ng/mL) [1]. They are very rare, representing only 2%–3% of
all PRL-secreting tumors [2]. They are most commonly found in young-
to middle-aged men with a male-to-female ratio of about 9:1 [1,2].
Giant prolactinomas can be highly invasive resulting in neurologic
complications [3]. On imaging they can present as aggressive skull
base tumors and pathologically they have the potential for sharing
common immunohistochemical (IHC) stains with other neuroendo-
crine neoplasms. Given their rarity and sometimes atypical presenta-
tion, diagnosis can be surprisingly delayed or even missed in some
cases, having the potential to lead to unnecessary surgery and/or radia-
tion. Correct diagnosis is paramount to ensuring appropriate dopamine
agonist therapy.sclose.
ogy, Diabetes and Nutrition,
ood Street, Howard Hall, Room
(Y. Mohtasebi).
. This is an open access article underCase report
A 27 year old female presented to the emergency roomwith progres-
sively worsening headache associated with nausea, vomiting and
2–3 days of left eye ptosis. Her condition rapidly declined; she developed
asymmetrical pupil dilation due to impending brain herniation, and
required intubation. Initial head CT and MRI showed a large destructive
mass centered at the central skull base,measuring 8.1 cm in craniocaudal
dimension with extensive bony destruction, intracranial and intra-
orbital extension, and acute obstructive hydrocephalus, with differential
diagnosis including destructive pituitary adenoma/carcinoma, sarcoma,
atypical destructive lymphoma or primary sinus neoplasm (Fig. 1).
An urgent ventriculostomy catheter was placed; she was started on
high dose dexamethasone and admitted to the neurosurgical ICU. Patient
underwent transnasal biopsy of the mass and initial pathology assess-
ment reported moderately to poorly differentiated sinonasal neuroen-
docrine carcinoma (SNEC). IHC staining was strongly positive for
CD56, synaptophysin and CAM5.2, focally positive for S-100 and
pancytokeratin and negative for chromogranin. Prolactin staining was
not performed. Positron emission tomography imaging was negative
for metastatic disease. Given the pathology results, location of the
tumor, and invasion to surrounding structures, neo-adjuvantthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Magnetic resonance image of head, T1-weighted sagittal post gadolinium,
demonstrating large heterogeneous skull base tumor with intra cranial, intra-orbital
and nasopharyngeal extension.
Fig. 2. A. Hematoxylin & eosin (H&E) stain, low magniﬁcation. B. Hematoxylin and eosin
(H&E) stain, high magniﬁcation. Cells demonstrating pink cytoplasm which is typical for
acidophilic cells. C. Prolactin stain.
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shrink the mass, followed by re-staging scan with subsequent potential
chemo-radiation for deﬁnitive treatment. Endocrinology was later
consulted due to a signiﬁcantly elevated prolactin level of
N4700 ng/mL which was measured a few days after admission. Further
history from thepatientwas pertinent for primary amenorrhea, galactor-
rhea and hirsutism. Review of her labs showed: serum prolactin
27,400 ng/mL (measured at 1:100 dilution) (Ref: 4.8–23.3 ng/mL), TSH
0.15 mIU/L (Ref: 0.47–4.68 mIU/L), FT4 0.7 ng/dL (Ref: 0.6–2.5 ng/dL),
LH b0.2 mIU/mL, FSH b0.7 mIU/mL, estradiol 5.3 pg/mL(Ref:
12.5–211 pg/mL), IGF-1 171 ng/mL (Ref: 78–270 ng/mL).
Hypothalamic–pituitary–adrenal (HPA) axis could not be assessed
since patient was on glucocorticoids. In view of her history and laborato-
ry ﬁndings, suspicion for a prolactin-producing adenoma was high. Re-
review of pathology was requested resulting in an amended report
which read, “after further clinicopathological correlation and additional
IHC staining,” this conﬁrmed the diagnosis of “pituitary prolactin adeno-
ma, acidophilic stem cell subtype”(Fig. 2). IHC stainingwas strongly pos-
itive for prolactin, CD56, synaptophysin, p53 and CAM5.2 and focally
positive for S-100, Ki-67 and pancytokeratin. It was negative for TSH,
LH, ACTH and chromogranin. There was scant positivity for GH. Chemo-
therapy was withheld, and she was started on cabergoline 0.5 mg twice
weekly, later up-titrated to 1mg 3 times per week and thyroid hormone
replacement. Five months after the start of cabergoline her prolactin
level is 118 ng/mL. Most recent MRI, ﬁve months post-start of
cabergoline, revealed marked reduction in tumor size to less than 4 cm
(Fig. 3). Clinically, she has had almost complete resolution of left eye pto-
sis and signiﬁcant improvement in visual ﬁelds. Her HPA axis, assessed
after discharge by ACTH stimulation test, was intact.
Discussion
Giant prolactinomas can cause both diagnostic and therapeutic chal-
lenges given their rarity, atypical presentation and potential radiologic
and pathologic overlap with other neuroendocrine neoplasms. Speciﬁc
deﬁnition of “giant” pituitary adenomas was introduced in 1979 by
Symon et al. for adenomas extending by more than 40 mm in any direc-
tion from the midpoint of the jugum sphenoidale. A tumor size criterion
is universally recognized and is important as these tumors will cause
speciﬁc neurological complications related to their invasive nature. The
most commonly used criterion is by far a tumor diameter of 40 mm or
more [1]. This particular size has been deﬁned arbitrarily by similarity
with the dimensions of the so-called giant cerebral aneurysms. As
serum hormone levels generally parallel tumor size, giant prolactinomasare typically associated with very high PRL concentrations, above
1000 ng/mL [1,4]. Unlike typical pituitary prolactinomaswhich classically
present with amenorrhea, infertility and galactorrhea in premenopausal
women, giant prolactinomas can present with neurologic complications
such as cranial nerve paresis, visual defects, hydrocephalus, exophthal-
mos or optic nerve compression due tomassive extension into surround-
ing structures [5,6]. In very rare cases when there is a large tumoral
extension into the nasopharynx, the diagnosis may be made through
biopsy of a nasal mass [7], as we reported in this case. Interestingly, in
Fig. 3. Magnetic resonance image of head. T1-weighted sagittal view, demonstrating
signiﬁcant decrease in tumor size.
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low grade neuroendocrine carcinoma, before diagnosis of prolactinoma
was conﬁrmed [7]. Therefore, although rare, giant prolactinoma should
always be considered in the differential diagnosis of any large skull base
tumor invading the nasopharynx. On the other hand, neuroendocrine
carcinoma of paranasal sinuses is an exceedingly rare malignancy,
accounting for 5% of tumors at this site [8]. They are known for their
aggressive behavior and poor response to treatment. In a retrospective
review of 28 patients with histological diagnosis of SNEC by Mitchell
et al. [8], the most common site of tumor origin was ethmoid sinus
followed by nasal cavity. Of note, in 10% of cases tumor originated from
sphenoid sinus which could mimic pituitary adenoma or other sellar
masses radiographically. Tumors of neuroendocrine differentiation
show common ultrastructural and immunohistochemical features,
including dense core secretory granules, staining for chromogranin,
synaptophysin, and keratin. Since prolactinomas also express common
neuroendocrinemarkers seen in other neoplasmswith neuroendocrine
differentiation, misdiagnosis as other neuroendocrine neoplasms is not
unexpected; particularly when the diagnosis is made through biopsy of
nasal mass rather than classical sellar mass. Correct diagnosis is partic-
ularly important, as dopamine agonists (DAs) are ﬁrst-line treatment
and can result in PRL normalization, marked reduction in tumor size
and even improvement of acute neurologic complications in majorityof cases [9]. In series with giant prolactinomas, resistance to cabergoline
varies between 16% and 50% [9]. DA resistance has been deﬁned as
failure to normalize PRL on maximally tolerated doses of DAs and the
absence of tumor size reduction ≥50%. Although most reported cases
in the literature typically respond to DAs, a normal PRL level may not
be achieved due to the large tumor size and very high PRL level at the
time of diagnosis. True resistance to DAs (complete absence of re-
sponse) is rare and may be indicative of malignancy. In another review
of individual responses of 97 patients with giant prolactinoma to DA
therapy, 60% (58/97) of patients achieved normoprolactinemia, 74%
(65/88) had marked reduction in tumor size and 96% (28/29) had im-
provement in visual ﬁeld. As we learned from this case, it is imperative
that clinical history, laboratory and imaging ﬁndings be reviewed, cor-
roborated and discussed with the pathologist so pertinent IHC can be
performed to conﬁrm the diagnosis.
Conclusion
Given their atypical presentation and potential for sharing common
IHC stains with other neuroendocrine neoplasms, giant prolactinomas ex-
tending into the nasal cavity canbemisdiagnosed as other neuroendocrine
neoplasmswhichmay develop at this site. This case highlights the impor-
tance of taking a detailed clinical history alongwith full pituitary hormonal
evaluation in the assessment of large skull base tumors. Accurate diagnosis
is paramount to prevent unnecessary chemotherapy, surgery and/or radi-
ation and to ensure implementation of dopamine agonist therapy.
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